The number of people with susceptibility test result for rifampicin in Sao Tome and Principe
Sao Tome and Principe: The number of people with susceptibility test result for rifampicin was 0 in 2021. ◆ Volatile
Latest (2021)
0
Change on year
down 100.0%
World rank
146th
of 155 countries
All-time high
24
in 2018
All-time low
0
in 2019
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Sao Tome and Principe, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
In 2021, the number of people with susceptibility test result for rifampicin in Sao Tome and Principe stood at 0. That is the lowest value across all 5 years on record.
Compared with earlier readings it is down 100.0% on the previous year and down 100.0% over five years.
Sao Tome and Principe ranks 146th of 155 countries on this measure, in the bottom quarter.
The number of people with susceptibility test result for rifampicin in Sao Tome and Principe, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 7 | — |
| 2018 | 24 | +242.9% |
| 2019 | 0 | -100.0% |
| 2020 | 1 | — |
| 2021 | 0 | -100.0% |
Sao Tome and Principe compared with similar countries
- Sao Tome and Principe's 0 is below the median for lower middle income countries, which is 2,804. (32 countries reporting)
- Sao Tome and Principe's 0 is below the median for Sub-Saharan Africa, which is 2,015. (33 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 10.33 | 0 | 24 | 3 |
| 2020s | 0.5 | 0 | 1 | 2 |
Countries ranked near Sao Tome and Principe
- 143 Saint Lucia 2 compare
- 143 Bermuda 2 compare
- 143 Andorra 2 compare
- 146 Grenada 0 compare
- 146 Niue 0
- 146 Mauritania 0 compare
- 146 Barbados 0 compare
- 146 Saint Kitts and Nevis 0 compare
- 146 Vanuatu 0 compare
- 146 South Sudan 0 compare
- 146 Antigua and Barbuda 0
- 146 Saint Vincent and the Grenadines 0 compare
More health data for Sao Tome and Principe
- Un projection of annual infant deaths, annual growth rate -6.25 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 1.35 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 793.5 deaths per 1,000 people (2090)
- Number of infants who die before age 1 15 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2021)
- Population ages 00-04, female, annual growth rate 1.58 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0651 units per person (2025)
- Population ages 00-04, male, annual growth rate 1.65 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Sao Tome and Principe?
- The number of people with susceptibility test result for rifampicin in Sao Tome and Principe was 0 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Sao Tome and Principe?
- The highest recorded value was 24 in 2018.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Sao Tome and Principe?
- The lowest recorded value was 0 in 2019.
- How does Sao Tome and Principe rank for the number of people with susceptibility test result for rifampicin?
- Sao Tome and Principe ranks 146th out of 155 countries with data for 2021.
- Where does this Sao Tome and Principe data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).